ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Adapting for the future of oncology
ICON experts Andreas Dreps and Martin Lachs share their thoughts on the future of cancer research and the importance of staying adaptive in PharmaPhorum's 'Future of Oncology 2020' magazine.
Navigating complexity in oncology cell and gene therapy clinical trials
This article featured in ClinicalOmics 'Insider's guide to precision medicine 2020' considers how cell and gene therapies are playing an increasingly important role in treating oncology patients.
An overview on rare disease research
ICON's Tim Clark and Will Maier examine the key clinical, regulatory, and commercial challenges associated with the development of therapies for the treatment of rare diseases.
The potential of activity trackers to bias study results
A thought leadership article authored by Marie McCarthy, Tim Clark and Peter Schueler on the impact of activity trackers on study participants and study endpoints.
A conversation with an expert in drug development
EBR interviews Colin Orford, Senior Vice President of Drug Development services at ICON, about finding an effective treatment for COVID-19.
Use of televisits in studies and related PV concerns
As a result of the COVID-19 pandemic televisits are becoming strongly considered as an alternative to on- site face-to-face visits, and as a new approach in virtual decentralised trials. ICON’s Xavier Fournie, a member of the EUCROF PharmacoVigilance Working Group, discusses the potential impact of televisits on pharmacovigilance (PV) processes.
Encouraging patient participation in real world studies
Real world data is rapidly becoming the latest frontier for life sciences companies for supporting regulatory filings and conducting drug safety surveillance. ICON experts discuss the critical role of patients and advocacy groups in the June issue of Pharmaceutical Market Europe.
Virtual Congresses – Facing up to virtual reality
The COVID-19 pandemic has challenged the traditional onsite congress engagement experience and forced pharma to rethink face to face events. Read more from Teresa Pena, PhD, Executive Principal Medical Communications in the June issue of Pharmaceutical Market Europe.
Running clinical trials for other drugs in the age of COVID-19
ICON’s CEO Steve Cutler, comments on in-home visits and virtual trials during the COVID-19 pandemic.
Going through changes
ICON's Angela Brown considers what manufacturers can learn from medical device regulation (MDR) and the effect it will have on the in vitro diagnotic landscape (IVD).